Document is current
Any future updates will be listed below
-
Authors
Ray-Coquard, Isabelle https://orcid.org/0000-0003-2472-8306
Kaminsky-Forrett, Marie-Christine https://orcid.org/0000-0002-0597-5160
Ohkuma, Ryotaro https://orcid.org/0000-0003-4121-2491
de Montfort, Aymeric https://orcid.org/0000-0001-9040-2385
Joly, Florence https://orcid.org/0000-0001-6168-4942
Treilleux, Isabelle
Ghamry-Barrin, Sarah
Bello-Roufai, Diana
Saintigny, Pierre
Angelergues, Antoine https://orcid.org/0009-0005-4876-918X
Michon, Lucas
Hardy-Bessard, Anne-Claire
Attignon, Valéry
Auclair, Jessie
Chemin, Gabriel https://orcid.org/0009-0003-6979-3037
Lainé, Alexandra https://orcid.org/0000-0002-8367-6115
Péré, Hélène
Veyer, David
Savoye, Aude-Marie
Berthet, Justine
Caux, Christophe
Lecuru, Fabrice
Dubois, Bertrand https://orcid.org/0000-0002-7859-4975
Bétrian, Sarah https://orcid.org/0000-0001-5369-9378
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb (no grant number applicable) SIRIC project (LYriCAN+, INCa-DGOS-INSERM-ITMO cancer_18003) Région Rhône Alpes
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 4 December 2025
First Online: 5 January 2026
Competing interests
: I.R.-C. reports honoraria from AbbVie, Advaxis, Agenus, Amgen, AstraZeneca, BMS, Clovis Oncology, Daiichi Sankyo, Deciphera, Genmab, GSK, Immunocore, Immunogen, MacroGenics, Mersana, MSD Oncology, Novartis, OxOnc, Pfizer, PharmaMar, PMV Pharma, Roche, Seagen, Sutro Biopharma, and Tesaro; consulting/advisory roles for AbbVie, Agenus, AstraZeneca, Blueprint Medicines, BMS, Clovis Oncology, Daiichi, Deciphera, Eisai, Genmab, GSK, Immunocore, Immunogen, MacroGenics, Mersana, MSD Oncology, Novartis, Novocure, OSE Immunotherapeutics, Pfizer, PharmaMar, Roche, Seagen, Sutro Biopharma, and Tesaro; research funding (to institution) from BMS, MSD Oncology, and Roche/Genentech; and travel/accommodations/expenses from Advaxis, AstraZeneca, BMS, Clovis Oncology, GSK, PharmaMar, Roche, and Tesaro. F.J. reports consulting/advisory roles for AstraZeneca, Janssen, Ipsen, Pfizer, MSD Oncology, Bristol-Myers Squibb, GSK, Astellas Pharma, Clovis, Amgen, Seagen, Bayer, Eisai, Sanofi/3A, and Viatris and travel/accommodation/expenses from Janssen, AstraZeneca, Ipsen, GSK, BMS, Eisai, MSD Oncology, and Chugai Pharma. D.B.-R. reports travel/accommodation/expenses from Daiichi Sankyo and Lilly. P.S. reports honoraria from HTG Molecular Diagnostics, Inivata, ArcherDx, Bristol-Myers Squibb, and Roche Molecular Diagnostics; research funding from Roche, AstraZeneca, Novartis, BMS Foundation, Illumina, and OmiCure; and travel/accommodation/expenses from Illumina, Bristol-Myers Squibb, AstraZeneca, and Roche. A.A. reports honoraria from AstraZeneca and GSK and travel/accommodation/expenses from GSK. A.-C.H.-B. reports consulting/advisory roles for AstraZeneca, Pfizer, Novartis, GSK, Eisai, Daiichi Sankyo/AstraZeneca, MSD, Gilead Sciences, AbbVie, and Regeneron. H.P. reports honoraria from MSD, Gilead, and ViiV; consulting/advisory role for MSD; and travel/accommodation/expenses from MSD and Gilead. F.L. reports consulting/advisory roles for GSK, AstraZeneca, and Pharma&, and research funding from MSD Oncology. B.D. reports research funding from MSD. The remaining authors report no conflict of interest.
